Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Fusion Antibodies Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Fusion Antibodies's earnings have been declining at an average annual rate of -19%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 7.6% per year.
Anahtar bilgiler
-19.0%
Kazanç büyüme oranı
-7.0%
EPS büyüme oranı
| Life Sciences Sektör Büyümesi | 36.9% |
| Gelir büyüme oranı | -7.6% |
| Özkaynak getirisi | -124.1% |
| Net Marj | -192.8% |
| Son Kazanç Güncellemesi | 31 Mar 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's Why We're Not At All Concerned With Fusion Antibodies' (LON:FAB) Cash Burn Situation
Aug 31
Here's Why We're Not Too Worried About Fusion Antibodies' (LON:FAB) Cash Burn Situation
Jan 25We Think Fusion Antibodies (LON:FAB) Can Easily Afford To Drive Business Growth
May 09Investors Who Bought Fusion Antibodies (LON:FAB) Shares A Year Ago Are Now Up 146%
Mar 17Companies Like Fusion Antibodies (LON:FAB) Can Afford To Invest In Growth
Jan 04Gelir ve Gider Dağılımı
Fusion Antibodies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 24 | 1 | -2 | 2 | 0 |
| 31 Dec 23 | 1 | -3 | 2 | 0 |
| 30 Sep 23 | 2 | -3 | 3 | 0 |
| 30 Jun 23 | 2 | -3 | 3 | 0 |
| 31 Mar 23 | 3 | -3 | 3 | 0 |
| 31 Dec 22 | 4 | -2 | 3 | 0 |
| 30 Sep 22 | 4 | -2 | 3 | 0 |
| 30 Jun 22 | 5 | -1 | 3 | 0 |
| 31 Mar 22 | 5 | -1 | 3 | 0 |
| 31 Dec 21 | 5 | -2 | 3 | 0 |
| 30 Sep 21 | 5 | -3 | 3 | 0 |
| 30 Jun 21 | 4 | -3 | 3 | 0 |
| 31 Mar 21 | 4 | -3 | 3 | 0 |
| 31 Dec 20 | 4 | -2 | 2 | 0 |
| 30 Sep 20 | 4 | -1 | 2 | 0 |
| 30 Jun 20 | 4 | -1 | 2 | 0 |
| 31 Mar 20 | 4 | -1 | 2 | 0 |
| 31 Dec 19 | 4 | -1 | 2 | 0 |
| 30 Sep 19 | 3 | -1 | 2 | 0 |
| 30 Jun 19 | 3 | -1 | 2 | 0 |
| 31 Mar 19 | 2 | -1 | 2 | 0 |
| 31 Dec 18 | 2 | -1 | 2 | 0 |
| 30 Sep 18 | 2 | -1 | 2 | 0 |
| 30 Jun 18 | 2 | -1 | 2 | 0 |
| 31 Mar 18 | 3 | -1 | 1 | 0 |
| 31 Mar 17 | 2 | 0 | 1 | 0 |
| 31 Mar 16 | 1 | 1 | 1 | 0 |
| 31 Mar 14 | 1 | 0 | 0 | 0 |
Kaliteli Kazançlar: FAB is currently unprofitable.
Büyüyen Kar Marjı: FAB is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: FAB is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Büyüme Hızlandırma: Unable to compare FAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: FAB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-9.9%).
Özkaynak Getirisi
Yüksek ROE: FAB has a negative Return on Equity (-124.15%), as it is currently unprofitable.